Myotonic syndrome
MONDO:001612061 clinical trials for this condition and its sub-types, 11 tagged with Myotonic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myotonic syndrome
-
Myotonic dystrophy 56 trials · 57 incl. sub-types
8 sub-types
- Myotonic dystrophy type 1 45 trials Sub-types →
- Myotonic dystrophy type 2 11 trials
- Congenital myotonic dystrophy 9 trials
- Childhood-onset Steinert myotonic dystrophy 2 trials
- Juvenile-onset Steinert myotonic dystrophy 2 trials
- Adult-onset Steinert myotonic dystrophy 0 trials
- Late-onset Steinert myotonic dystrophy 0 trials
- Myotonic cataract 0 trials
-
Nondystrophic myotonia 4 trials
-
Potassium-aggravated myotonia 0 trials
3 sub-types
- Acetazolamide-responsive myotonia 0 trials
- Myotonia fluctuans 0 trials
- Myotonia permanens 0 trials
Most studied deeper sub-types
-
New hope for muscle disease: experimental drug VX-670 enters human trials
Disease control OngoingThis early-stage trial tests the safety and tolerability of a new drug called VX-670 in 52 adults with myotonic dystrophy type 1 (DM1), a genetic condition that causes muscle weakness and other problems. Participants receive either VX-670 or a placebo, and researchers will monito…
Phase 1/2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for DM1: Long-Term trial of AOC 1001 underway
Disease control By invitation onlyThis phase 3 study is testing the long-term safety and effectiveness of an experimental drug called AOC 1001 (del-desiran) for people with myotonic dystrophy type 1 (DM1), a genetic muscle disorder. The trial enrolls 230 adults who have completed a prior AOC 1001 study and will r…
Phase 3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Vertex tests long-term safety of VX-670 for muscle disease
Disease control By invitation onlyThis study tests the long-term safety and effectiveness of an experimental drug called VX-670 in adults with myotonic dystrophy type 1 (DM1). Participants who completed a previous VX-670 study can join. The drug is given through a vein, and researchers will monitor side effects a…
Phase 2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC